There are 1105 resources available
Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Presenter: Masatoshi Kudo
Session: ESMO 2024 Highlights session 1
Resources:
Slides
Webcast
Q&A and discussion
Session: ESMO 2024 Highlights session 2
Resources:
Webcast
Q&A and discussion
Session: ESMO 2024 Highlights session 1
Resources:
Webcast
Welcome and introduction
Presenter: Ross Soo
Session: Johnson and Johnson International (Singapore) Pte Ltd, - Pioneering advances in EGFRm NSCLC therapy: Navigating the future of patient care
Resources:
Webcast
Welcome and introduction
Presenter: Ilaria Colombo
Session: ESMO Colloquium supported by AbbVie - Hot topics in ovarian cancer: Platinum resistance and emerging therapies
Resources:
Slides
Webcast
Overview of unmet needs in EGFRm advanced NSCLC in Asia
Presenter: Ross Soo
Session: Johnson and Johnson International (Singapore) Pte Ltd, - Pioneering advances in EGFRm NSCLC therapy: Navigating the future of patient care
Resources:
Webcast
Insights from the biology of cancer of the ovaries, fallopian tube and peritoneum: The promise of biomarkers
Presenter: Kosei Hasegawa
Session: ESMO Colloquium supported by AbbVie - Hot topics in ovarian cancer: Platinum resistance and emerging therapies
Resources:
Slides
Webcast
Treatment advances in common EGFRm advanced NSCLC
Presenter: Alexander Spira
Session: Johnson and Johnson International (Singapore) Pte Ltd, - Pioneering advances in EGFRm NSCLC therapy: Navigating the future of patient care
Resources:
Webcast
A clinical case of a patient with platinum-resistant ovarian cancer: Resistance pathways and state-of-the-art treatment options
Presenter: Asima Mukhopadhyay
Session: ESMO Colloquium supported by AbbVie - Hot topics in ovarian cancer: Platinum resistance and emerging therapies
Resources:
Slides
Webcast
The evolving treatment landscape for advanced NSCLC with EGFR exon20insertion mutations
Presenter: Tony S.K. Mok
Session: Johnson and Johnson International (Singapore) Pte Ltd, - Pioneering advances in EGFRm NSCLC therapy: Navigating the future of patient care
Resources:
Webcast